CARLSBAD, CA-(Marketwired — June 02, 2016) — International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical, non-human primate study.
The data demonstrates the safety and efficacy of the company’s proprietary ISC-hpNSC® readily expandable neural stem cell derived treatment of Parkinson’s disease.
«The publication of the data in the peer-reviewed and highly-respected journal, Cell Transplantation, brings to conclusion the preclinical stage of ISCO’s Parkinson’s disease program. The data provides further evidence that parthenogenetic neural stem cells can be effective in treating the symptoms of Parkinson’s disease and, along with the previously safety data, formed the basis of our application to the Australian regulatory authorities to move this program into the clinic," said Russell Kern, Ph. D., ISCO’s Chief Scientific Officer.
The 12-month GLP study demonstrated the safety and efficacy of transplanting ISC-hpNSC® into non-human primates with induced moderate to severe clinical Parkinson’s disease symptoms. Transplantation of neural cells was safe and well tolerated by the animals with no dyskinesia, tumors, ectopic tissue formation or other test article related serious adverse events. It was shown that ISC-hpNSC® improved Parkinson’s disease symptoms by increasing the number of dopaminergic neurons and dopamine concentration in the brain through neurotrophic support and dopamine neuron replacement. This data from this study was closely reviewed by the Australian Therapeutic Goods Administration (TGA) and supported the clinical trial approval of ISC-hpNSC® for the treatment of Parkinson’s disease (ClinialTrials.gov NCT02452723).
Source:
http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=81759&GoTopag...
